National Center for Advancing Translational Sciences — CFDA 93.350

Translational-science obligations at $5.20 billion

USAspending.gov records $5,195,080,963.66 in obligations under CFDA 93.350. Seven hundred sixty-eight awards produce that stock. A simple average is about $6.76 million per award — larger than many investigator-initiated research rows and consistent with center and consortium actions. That average is a quotient of two packet totals, not a typical trial budget.

The assistance-listing title is NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES. CFDA 93.350 is the identifier. Other biomedical-research listings, if tagged under other CFDA numbers, are not included in the $5.20 billion.

USAspending.gov records the $5,195,080,963.66 obligation stock for CFDA 93.350 together with 768 awards, 264 recipients, and 40 states. Keep NCATS on 93.350 when quoting these four facts. Outlays remain a separate column.

Two hundred sixty-four recipients, 40 states

Two hundred sixty-four recipients share 768 awards, or about 2.9 award records per recipient on average. Splitting $5.20 billion evenly would assign about $19.7 million per recipient. Research institutions are the unit this kind of listing usually names; the packet does not list the 264.

Forty states in the geographic count is narrower than many research files. Place-of-performance on 40 cells reports where 93.350 awards are labeled in this extract. Dollar amounts by place are on the program table.

Award count is not a trial count

Among research listings, 93.350 is mid-density: 768 rows against 264 recipients. Award count is a weak proxy for “number of translational studies.” Recipients (264) are the organizational headcount.

The packet does not report trial enrollments, assay counts, or approvals. Citing 768 as trials or drugs would be a unit error. Keep the units straight: dollars, awards, recipients, states.

Obligations versus research outlays

The $5.20 billion is an obligation total from USAspending.gov. Outlays — cash paid against NCATS awards — are not in the packet. An institution can show a large obligation stock while draws follow a multi-year grant calendar. Deobligations and upward adjustments both move the total.

Use CFDA 93.350 to size this translational-sciences listing. Do not use it as a pipeline dashboard. This page reports the obligation book tagged 93.350.

What the 93.350 tables omit

The NCATS hub lists award-backed obligations from USAspending.gov. It is not a trial registry, not a drug pipeline, and not a publication index. Series that never appear as assistance awards will not show up in the $5,195,080,963.66.

Place-of-performance on 40 states is a coding field. Recipient dollars, if shown on the hub, are still obligation amounts, not cash already spent on assays or staff.

Where the 93.350 table lives

The National Center for Advancing Translational Sciences program page overlays these four facts. The all-programs index ranks 93.350 among other assistance listings. Agency pages show awarding-agency rollups. For 93.350 only, start on the program page.

CFDA 93.350’s 768 awards spread $5,195,080,963.66 across 264 recipients and 40 states. Quote award count as a record count, recipient count as the organizational headcount, and dollars as obligations from USAspending.gov. Forty coded jurisdictions is the geography story. Outlays remain a separate column. Source: USAspending.gov assistance awards. The four-fact citation for CFDA 93.350 is the obligation stock on this extract, together with the award, recipient, and state counts already named above. Do not convert those figures into outlays, and do not treat award count as a service census. Start on the program page for CFDA 93.350 before ranking this listing against other assistance rows. Obligations remain the reporting concept on this extract; outlays are not stored in the packet facts. Award count is a record count; recipient count is the organizational headcount; the state figure is a coded-jurisdiction count from USAspending.gov. Deobligations and upward adjustments both move the obligation stock; this page does not publish remaining balances. Internal links on this overlay point to the program page, the all-programs index, and agency rollups. SpendingVault indexes USAspending.gov assistance awards; it does not convert this CFDA into a performance scorecard. If a number you expected is missing, the usual cause is a different reporting concept than obligations on assistance awards. Name the series as obligations whenever you quote the dollar stock, the award count, the recipient field, or the state count.

Questions

How much is obligated for NCATS CFDA 93.350?

USAspending.gov records $5,195,080,963.66 in obligations for CFDA 93.350. SpendingVault indexes 768 awards, 264 recipients, and 40 states. The figure is an obligation sum, not an outlay and not a trial count. CFDA 93.350’s $5.20 billion is the USAspending obligation stock.

How many awards does CFDA 93.350 carry?

The listing shows 768 awards against 264 recipients. A simple average is about $6.76 million per award. Award count is not a trial or drug count. Recipient dollars are on the program page. USAspending.gov assistance awards on SpendingVault are the source for this obligation stock.

Why does CFDA 93.350 show only 40 states?

The extract codes 40 states on place-of-performance. That stored geographic count is narrower than many nationwide research files. It reports labels on 93.350 awards in this extract, not a ranking of biomedical capacity. USAspending.gov assistance awards on SpendingVault are the source for this obligation stock.

Is $5.20 billion already spent on translational science?

Not necessarily. Obligations are commitments. Outlays are payments. CFDA 93.350’s indexed total is the obligation stock from USAspending.gov. This page does not report cash drawn or pipeline results. The $5.20 billion on 768 awards is the obligation figure. USAspending.gov assistance awards on SpendingVault are the source for this obligation stock.